Description

PT-141, also known as Bremelanotide (in clinical terms), is a highly modified synthetic derivative of the alpha-melanocyte-stimulating hormone. It has undergone rigorous clinical trials as a potential treatment for hypoactive sexual desire disorder in both males and females, as well as acute hemorrhage. PT-141 acts as an agonist for the melanocortin-4 and melanocortin-1 receptors, exhibiting the ability to enhance sexual arousal and stimulate the immune system.

This product requires reconstitution.